Alembic Pharmaceuticals gets final nod from USFDA for Pirfenidone Tablets

24 May 2022 Evaluate

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Pirfenidone Tablets, 267 mg and 801 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Esbriet Tablets, 267 mg and 801 mg, of Genentech, Inc. (Genentech).

Pirfenidone Tablets are indicated for the treatment of idiopathic pulmonary fibrosis (IPF). Alembic had previously received tentative approval for this ANDA. Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification. It may not• be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses.

Pirfenidone Tablets, 267 mg and 801 mg have an estimated market size of $ 548 million for twelve months ending December 2021. Alembic has settled the case with Genetech and will launch its generic as per the terms of settlement. The company has a cumulative total of 167 ANDA approvals (144 final approvals and 23 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

1121.40 -7.35 (-0.65%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.